Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Xencor (XNCR)

Xencor appoints Raymond Deshaies, Ph.D., former Amgen research head, to board

Neutral Impact 2 of 5 leadership Written later

On July 31, 2025, Xencor appointed Raymond J. Deshaies, Ph.D., as a new member of its Board of Directors. He will receive an initial stock option grant with a Black Scholes value of $550,000 and a $50,000 annual cash retainer for board service.

Key points

  • Appointed to the board on July 31, 2025; he recently served as senior vice president of global research at Amgen Inc.
  • Initial option grant has a Black Scholes value of $550,000; one-third vests on the one-year anniversary, with the rest vesting in 24 monthly installments, fully vested at three years.
  • Receives a $50,000 annual cash retainer and is eligible for future equity compensation.

The filing

CompanyXencor (XNCR)
Form8-K, current report
Filed with the SECJul 31, 2025, 4:02 PM ET
Accession number0001326732-25-000063

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.